Dual Wavelength and First Order Derivative Spectrophotometric Methods for Simultaneous Estimation of Rivaroxaban and Aspirin in Synthetic Mixture

Main Article Content

Heba Zhdan
Nazira Sarkis

Abstract

Two simple, sensitive, accurate and precise spectrophotometric methods were developed and validated for simultaneous estimation of binary mixture of Rivaroxaban and Aspirin in their pure form and synthetic mixture in difficult ratio 1:20(Rivaroxaban: Aspirin). The first method is the dual wavelength method, where 250 nm and 286.44 nm were selected as λ1 and λ2 for determination. And the two wave length for determination of Aspirin were 243.53 nm and 259.2 nm. The linearity range was studied over concentration ranges (2 – 12) μg/mL and (40-240) μg/mL for Rivaroxaban and Aspirin respectively in both methods, with correlation coefficients not less than 0.9996 and up to 0.9999 respectively in a row. The limit of detection (LOD) and limit of quantification (LOQ) were 0.24μg/mL and 0.82 μg/mL for Rivaroxaban and for Aspirin were7.03 μg/mL and 22.01 μg/mL respectively in the first method. The second method is First order derivative. The wavelengths 275.25 nm and 250 nm were selected as zero crossing point to determine Rivaroxaban and Aspirin in a row. The LOD and LOQ were 0.31 μg/mL and 0.95 μg/mL for Rivaroxaban; and for Aspirin was found to be7.13 μg/Ml and 21.60μg/mL respectively. The two methods were successfully validated as per ICH guidelines. Both methods were simple, sensitive and rapid.

Keywords:
Rivaroxaban, aspirin, dual wave length, first order derivative, synthetic mixture

Article Details

How to Cite
Zhdan, H., & Sarkis, N. (2020). Dual Wavelength and First Order Derivative Spectrophotometric Methods for Simultaneous Estimation of Rivaroxaban and Aspirin in Synthetic Mixture. International Research Journal of Pure and Applied Chemistry, 21(24), 48-54. https://doi.org/10.9734/irjpac/2020/v21i2430334
Section
Original Research Article

References

European Medicines Agency (EMEA). CHMP Assessment Report for Xarelto. Accessed; 2010.

Available:ttp://www.emea.europa.eu/humandocs/PDFs/EPAR/ xarelto/H-944-en6.pdf. 2008.

Hennekens CH, Sechenova O, Hollar D, Serebruary VL. Dose of aspirin in the treatment and prevention of cardiovascular disease: Current and future directions, Journal of Cardiovascular and Pharmacology. 2006;3(11):170–176.

Summary LAY. Rivaroxaban (Xarelto) in combination with aspirin for prevention of major cardiovascular events in coronary or peripheral artery disease. National Institute for Health Research. 2017;1–8.

FDA Okays Rivaroxaban Plus Aspirin for Chronic CAD. PAD – Medscape. 2018.

Available:https://www.medscape.com/viewarticle/903344.

Srinivasrao V, Girase YN, Diptisoni. Development and validation of stability indicating RP-HPLC method for rivaroxaban and Its impurities. SOJ Biochemistry. 2018;4(1):1-6.

Sunny A, Sreedhar C, Akkama HG, Mahapatra A. Development of new analytical method and validation for quantitative estimation of rivaroxaban in formulation and bulk drug. International Journal of Scientific Research in Education. 2017;5(5):6469-6478.

Avachat AM, Yamgar MP. RP-HPLC method development and validation for the estimation of rivaroxaban in bulk and tablet dosage form. World Journal of Pharmacy and Pharmaceutical Sciences. 2017;6(8):1775-1784.

Shivashankar V, Gandhimathi M, Ravi TK Development of validated RP-HPLC method for estimation of rivaroxaban in pharmaceutical formulation, International Journal of Pharmaceutical Research and Analysis. 2015;4(4):406-410.

Sahoo S, Mekap SK. Assay comparison of rivaroxaban by new HPLC method with an existing method in tablet dosage form. Pharmaceutical and Biological Evaluations. 2017;4(3):180-182.

Arous B, Al-Mardini MA, Ghazal H, Al-Lahham F. Sability-indicating method for the determination of rivaroxaban and its degradation products using LC-MS, and TLC. Research J. Pharm and Tech. 2018;11(1):3.

Seshamamba BSV, Sekaran CB. Spectrophotometric quantification of direct factor xa inhibitor, rivaroxaban, in raw and tablet dosage form. Glob Drugs and Therap. 2017;2(3):1-8.

Çelebier M, Kaynak MS, Altinöz S, Sahin S. UV spectrophotometric method for determination of the dissolution profile of rivaroxaban. Dissolution Technologies. 2014;21:56-59.

Sekaran CB, Bind VH, Damayanthi MR, Sireesha A. Development and validation of UV spectrophotometric method for the determination of rivaroxaban, Der Pharma Chemica. 2013;5(4):1-5.

Kalshetti MS, Kasabe S, Chauhan N, Dhanshri S, Kale B. Development and validation of RP-HPLC method for simultaneous estimation of aspirin and omeprazole in dosage. International Journal of Research in Pharmacy and Pharmaceutical Sciences. 2017;2(4): 45-5.

Kiran KK, Supriya D, Divya D, Rani D, Munni GN. Analytical method development and validation for the estimation of aspirin and omeprazole using RP-HPLC method. Intercontinental journal of pharmaceutical Investigations and Research. 2017;4(1):44-71.

Mabunni SK, Kumari AS, Kiran PC. A new RP-HPLC method development and validation for simultaneous estimation of aspirin and omeprazole in bulk and pharmaceutical dosage forms. Intercontinental Journal of Pharmaceutical Investigations and Research. 2017; 4(3):240-245.

Chodvadiya FJ, Thula KC, Maheshwari DG. Simultaneous estimation of aspirin and lansoprazole by RP–HPLC method, International Journal of Recent Scientific Research. 2015;6(4):3385-3390.

Rajput S, Fanse S. RP-HPLC method for simultaneous estimation of lansoprazole and aspirin in bulk and laboratory mixture. Journal of Advanced Pharmacy Education & Research. 2015;5(2):240-245.

Kumar S, Jamadar LD, Bhat K, Musmade P, Vasantharaju SG. Analytical method development and validation for aspirin. International Journal of Chem Tech Research. 2010;2(1):389-399.

Tsikasa D, Tewesa KS, Gutzkia FM, Schwedhelma E, Greipel J, Frolich JC. Gas Chromatographic-tandem mass Spectrometric determination of acetylsalicylic acid in human plasma after oral administration of low-dose aspirin. Journal of Chromatography B: Biomedical Sciences and Applications. 1998;709:79-88.

Kokot Z, Burda K, Simultaneous determination of salicylic acid and acetylsalicylic acid in aspirin delayed-release tablet formulations by second-derivative UV spectrophotometry. Journal of Pharmaceutical and Biomedical Analysis. 1998;8:871–875.

Murtaza G, Alikhan S, Shabbir A, Mahmood A, Farzana K, Malik NS, et al. Development of a uv-spectrophotometric method for the simultaneous determination of aspirin and paracetamol in tablets. Scientific Research and Essays. 2011;6(2):417-421.

Purkar AJ, Balap AR, Jadhav SB, Chaudhari PD. Development and validation of uv spectrophotometric method for simultaneous determination of rosuvastatin calcium and aspirin in its pure and pharmaceutical dosage forms. International Journal of Pharmaceutical and Chemical Sciences. 2012;1(3):1008-1012.

Patta S, Afreen S, Tappa S, Nagarajan G, Gnanaprakash K. Simultaneous estimation of aspirin and omeprazole in bulk by uv-spectroscopy. Journal of Drug Delivery & Therapeutics. 2017; 7(3):87-91.

Ahmed M, Biswas MHU, Rahman MM, Sadik G. Development of a spectrophotometric method for the determination of aspirin in blood sample. The Sciences. 2001;1(2):61-62.

Dhudashia KR, Patel AV, Patel CN. Simultaneous uv spectrophotometric estimation of clotrimazole and beclomethasone dipropionate in their combined dosage forms by Q Ǧ absorption ratio, dual wavelength and first order derivative method. Inventi Journal. 2012;(2):94–97.

Patel RD, Maheshwari DG. Dual wavelength spectrophotometric method for simultaneous estimation of torsemide and amiloride hydrochloride in their combined dosage form. Der Pharma Chemica. 2014;6(2):43-49.

Lotfy HM, Hegazy MA, Rezk MR, Omran YR. Comparative study of novel versus conventional two-wavelength spectrophotometric methods for analysis of spectrally overlapping binary mixture. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2015;148: 328–337.